Leiden, Netherlands-based Pharming Group (NASDAQ:PHARM) provided 2026 financial guidance and detailed its rare disease pipeline at its Investor Day on February 3, 2026.
The company guided for 2026 revenue in the range of $405 million to US$425 million, representing 8% to 13% growth over 2025, and operating expenses of $330 million to $335 million, reflecting increased investment in R&D for its late-stage programs leniolisib and napazimone (KL1333).
Management also emphasized continued commercial momentum for Joenja (leniolisib) in activated phosphoinositide 3-kinase delta syndrome (APDS) and RUCONEST in hereditary angioedema (HAE), while advancing key clinical milestones.
Top-line readouts from the Phase II study of leniolisib are expected in the second half of 2026, and the pivotal FALCON trial of napazimone (KL1333) in primary mitochondrial myopathy remains on track for a 2027 readout.